Dual sourcing of primary packaging components in biopharma manufacturing: A case study

Abstract

- The biopharmaceutical industry has weathered multiple challenges over the past 4 years. One of the major pressure points that manufacturers of parenteral products have had to overcome is supply chain issues – namely with primary packaging components. Biopharma manufacturers must consistently act and react to such market pressures
- This poster will discuss how our company has challenged some of the "status quo" in the sterile primary packaging component space; in particular, we will discuss how we have updated our governance system to address bringing sterile products to market in ways that can be more nimble and effective – including dual-sourcing of suppliers of primary packaging components – ultimately bringing lifesaving medicines and vaccines to our patients faster and more reliably

Objectives

- To understand the unique challenges of single-sourcing and dual-sourcing primary packaging components for parenteral products
- To address the "status quo" present in many of our companies that is, going to market with a single primary packaging component image
- To explain the risks of going to market with a single primary packaging component image
- To identify ways to mitigate the risks of being single-sourced, including internal governance strategies

Case study

Background


- Multiple Merck Manufacturing Division (MMD) projects, both technical and strategic, indicated that dual-sourcing of primary packaging components (PPC) is required in the sterile Drug Product space
- MMD leadership request was to evaluate the Merck network and develop mitigations to address PPC dual-sourcing across all modalities • Global Technical Operations created a steering committee that requested an overview of the landscape for PPC duality projects (active,
- proposed) as well as a definition of success and consolidation of opportunities in large molecule (LM) and small molecule (SM) products
- MMD leadership requested an overview of the PPC duality landscape for pipeline products to support development of a governance document as well as principles to allow for exceptions to that document

Summary of the PPC landscape for inline and pipeline products

- Inline products are predominantly single-sourced for elastomers and cap/seals
- Broad subset of inline products that are dual-sourced for glass (dependent on site and image, LM vs SM, internal vs external)
- Pipeline products are predominantly single-sourced for elastomers and cap/seals; in addition, these are mainly single-sourced for glass
- Review mitigations, developed in collaboration with Merck Research Laboratories, Sterile Drug Product Commercialization, Packaging Commercialization, Supplier Development & Performance Management, Procurement, and Global Tech Ops (LM and SM)

THE LEGACY SYSTEM INTRODUCED POTENTIAL UNINTENDED RISK TO SUPPLY


Drivers for a second supplier



• Dual-source strategy not only mitigates the above risks, but the strategy also benefits pharmaceutical companies through increased business and quality engagement, as well as protection against potential supplier retaliation

Opportunities to fortify duality for pipeline products are captured in *Technical Guidance Document*

Previous state:




Proposed additions:


- Design in PPC duality upstream in the drug product life cycle
- Align the Exception process by stage gates
- Approval by committee for the Exception process and re-evaluation at stage gates or milestones Tactical Execution Governance and Tactical Execution Governance + Value Chain Governance
- Develop principles to govern the Exception process; eg, technical/supply readiness, program strategy, cost, etc
- Generate awareness of Technical Guidance Document through expanded reviews and engagement with key leaders to ensure duality is recognized and endorsed at appropriate forums


Product life cycle and governance structures

Commercialization stages



Strategic governance review





Acknowledgments

Raul Dominguez: MMD Global Procurement


Paul Kolosick. Eric Westhaus. Laura Bentley, Andrea Straka: MMD Global Science Technology Services/Components COE Ananth Sethuraman, Dave Owen: MMD Sterile Drug Product Commercialization Karen Burton, Brian McSweeney: MMD Supplier Development & Performance Management

Natalie Christian: MMD Manufacturing Strategy

Tim Schultz, BS, MBA Merck & Co., Inc., Rahway, NJ, USA

Chris Roberts: MMD Global Science Technology Services Stephen Conway: MMD Packaging Commercialization John Haines: MMD Value Chain Management Allen Templeton: MRL Preclinical Development Caroline McGregor: MRL Analytical R&D

Revisions to Technical Guidance Document created a paradigm shift for the organization



Completed significant revisions to *Technical Guidance Document* to better position pipeline products

Status	
	Design-in PPC duality upstream
	Aligned the Exception process b
	Approval by committee for the E Execution Governance + VCM
	Developed principles to govern
	Expanded reviews and engager Laboratories, Merck Manufactur

Selection of PPCs

Principles for component selection:

	Product/Marke
	Use of standar
	 Clinical conside Program pro Technical construction Availability of Speed to matrix
	Commercial co • Location of p • PPQ batch f • Availability o • Assessment

Proposed revisions

m in the drug product life cycle

by Development and Commercialization stage gates

Exception process and re-evaluated at stage gates or milestones – Tactical Execution Governance and Tactical

n the Exception process; eg, technical/supply readiness, program strategy, cost, etc

ement with key leaders to ensure duality is recognized and endorsed at appropriate forums (Merck Research uring Division, Global Procurement, Supplier Development, Global Tech Ops, etc)

Selection of appropriate PPCs is a critical decision: Technical, strategic, quality, and business elements must be considered when determining the final image

et Level Segmentation (rank on Company's prioritization matrix)

rdized PPC (leverage known technical/supply capabilities, economies of scale)

derations

obability of success

constraints of PPC (eg, non-standardized lyophilization vials)

of drug substance

arket

onsiderations

primary stability batch fills – site-agnostic GMP facility (including all GMP sites)

fills utilizing matrix approach for PPC

of drug substance

nt of volume projections/LROP vs analytical/stability testing costs